Navigation Links
Baraclude (entecavir) Therapy Resulted in Undetectable Levels of,Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment

E is right for her. A woman should not breastfeed if she is taking BARACLUDE.

People should discuss with their healthcare provider all prescription and non-prescription medicines, vitamins, herbal supplements, and other health preparations they are taking or plan to take. BARACLUDE(R) (entecavir) may interact with medicines that leave the body through the kidneys. The most common side effects of BARACLUDE in clinical studies were headache, tiredness, dizziness, and nausea.

This list of side effects is not complete at this time because BARACLUDE is still under study. People should report any new or continuing symptom to their healthcare provider. BARACLUDE should be taken once daily on an empty stomach (at least two hours after a meal and two hours before the next meal). To learn more about BARACLUDE and for Full Prescribing Information, including boxed WARNINGS, please visit http://www.bms.com.

Bristol-Myers Squibb is a global pharmaceutical and related health care products company whose mission is to extend and enhance human life.

BARACLUDE(R) (entecavir) is a trademark of Bristol-Myers Squibb Company.

Full prescribing information for BARACLUDE, including boxed WARNINGS, is available at http://www.bms.com.

CONTACT: Media, Sonia Choi, Corporate Communications, +1-609-252-5132,, or Investors, John Elicker, Investor Relations,+1-212-546-3775, , both of Bristol-Myers Squibb sonia.choi@bms.com john.elicker@bms.com

Web site: http://www.bms.com/

Ticker Symbol: (NYSE:BMY)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load Reduction Compared to Adefovir at 48 Weeks in Study of Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients
2. Gene Chips to Detect CYP Variations: A New Step Toward Customized Medical Therapy.
3. Breast Cancer and HER-2/neu: Diagnostic Tools for Targeted Therapy
4. Pixantrone Combination Therapy for First-line Treatment of Aggressive Non-Hodgkins Lymphoma Results in Reduction in Severe Toxicities Including Heart Damage When Compared to Doxorubicin-based Therapy
5. Gene Therapy Eradicates Pancreatic Cancer in Preclinical Trial Targeting Systems Success in Mouse Model Reported in Cancer Cell
6. Response Genetics Announces Publication of a Phase III Clinical Trial Demonstrating That Low Levels of ERCC-1 Help to Predict Likelihood of Response to Cisplatin-Based Therapy in Lung Cancer
7. New Phase 3 Study Published in The Lancet Evaluates Efficacy and Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination Therapy in Treatment-Experienced Adults With HIV
8. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
9. Studies of Drug Resistance May Lead to Individual Therapy for Rare Cancers
10. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
11. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
Post Your Comments:
(Date:7/23/2014)... , Indien, July 23, 2014 /PRNewswire/ ... additional scope für Arbeiten für Sadara Chemical ... comprehensive Engineering Information System innerhalb des integrierten ... Dieser award of additional scope im Wert ... des zuvor abgeschlossenen Vertrags dar, dessen Wert ...
(Date:7/22/2014)... July 23, 2014   - Investment ... Pharmaceutical Co., Ltd. (hereinafter "Taiho"), a fully-fledged oncology pharmaceutical ... be investing US$30 million in Remiges BioPharma Fund (hereinafter ... Taiho has a long history of developing ... and cancer patients. Our development of TAS-102 is an ...
(Date:7/22/2014)... , July 22, 2014  Nektar Therapeutics (Nasdaq: ... second quarter ended June 30, 2014 on Thursday, July 31, ... Robin , president and chief executive officer, will host a ... Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... conference call can be accessed through a link that is ...
Breaking Medicine Technology:Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 2Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 3Rolta gewinnt Follow-on Award für Engineering Systems für Sadara, Saudi-Arabien im Wert von mehreren Millionen Dollar 4Taiho Pharmaceutical Invests US$30 Million in Remiges BioPharma Fund, LP 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 2Nektar to Announce Financial Results for the Second Quarter 2014 on Thursday, July 31, 2014, After Close of U.S.-Based Financial Markets 3
... Healthcare announced today that it has acquired Alpha Care ... health economics and policy solutions for pharmaceutical, medical device, ... will expand its health economics, pricing and market access ... office in Berlin, Germany, will allow Boston Healthcare to ...
... being released by the U.S. Food and Drug Administration: ... Fast Facts FDA ... to feed SimplyThick, a thickening agent for management of ... The product may cause necrotizing enterocolitis (NEC), a life-threatening ...
Cached Medicine Technology:Boston Healthcare Acquires Alpha Care GmbH, Expanding Health Economics, Pricing and Reimbursement Consulting Presence in Europe 2FDA: Do Not Feed SimplyThick to Premature Infants 2FDA: Do Not Feed SimplyThick to Premature Infants 3
(Date:7/23/2014)... 23, 2014 PartnerTech Inc. , ... Lawrenceville, Georgia, welcomed Andreas von Uexkull to their facilities, ... the U.S. von Uexkull, a top trade official from ... of the U.S. to bring awareness and insight to ... Investment Partnership (TTIP). , As an expert on ...
(Date:7/23/2014)... (PRWEB) July 23, 2014 Previously, the crew ... pencil and a spreadsheet. Now, the department’s 53 ... Scheduling and Workforce Management system. , “Scheduling our personnel with ... It was hard to keep track of when people could ... this time to this time, and we would have to ...
(Date:7/23/2014)... Controlling pain during childbirth and post delivery may reduce ... a Northwestern Medicine perinatal psychiatrist, in a July 23 ... Wisner,s editorial is based on a new Chinese study ... anesthesia during a vaginal delivery had a much lower ... the epidural. , "Maximizing pain control in labor and ...
(Date:7/22/2014)... (PRWEB) July 22, 2014 Print ... Print Audit Facilities Manager web portal. Facilities Manager ... releases of the software as well as numerous ... , Print Audit Facilities Manager is a powerful, ... to remotely collect meter reads, automate supplies fulfillment ...
(Date:7/22/2014)... Recently, iFitDress.com, a popular supplier of wedding dresses and ... of white party dresses to its product category. ... now available on its website. As a special offer, all ... can get a discounted rate, up to 54% off. , ... customers, so its marketing specialist believes the new white party ...
Breaking Medicine News(10 mins):Health News:Swedish Official Tours PartnerTech’s U.S. Facility 2Health News:Swedish Official Tours PartnerTech’s U.S. Facility 3Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 2Health News:This Fire Department Allows Personnel to Schedule Themselves - Saving Administration Up To 60 Hours a Month 3Health News:Controlling childbirth pain tied to lower depression risk 2Health News:Print Audit® Releases Facilities Manager 3.1.0R 2Health News:Elegant White Party Dresses Now Provided by Distinguished Company iFitDress.com 2
... , SCOTTSDALE, Ariz., July 15 ... Healthcare Trust of America, Inc.) (the "REIT"), a self-managed non-traded ... and sale agreement (the "Agreement") to acquire a 16 building ... Carolina. The transaction involves approximately 855,000 square feet of medical ...
... , , CARY, ... CRTX ), a specialty pharmaceutical company focused on ... respiratory and related markets, today announced that it has ... Drug Administration (FDA) for an extended-release antitussive product (CRTX ...
... , , , ... on the data presented today, the U.S. Food and Drug Administration (FDA) ... HCI liposome injection) and docetaxel did not provide ... or metastatic breast cancer. , , Women ...
... , WESTBROOK, Maine, July 15 IDEXX Laboratories, ... 2009 second quarter financial results for Friday, July 24, at approximately 7:00 ... 9:00 a.m. (eastern) on that day. , , ... through a link on the IDEXX Web site, www.idexx.com. An archived edition ...
... , , , ... AHS ), the leading healthcare staffing company in the United States, ... Financial Officer (CFO), effective August 10, 2009. Bailey brings nearly 30 ... insurance and pharmaceutical industries. , , Mr. ...
... method still shows promise, scientists say , WEDNESDAY, ... hopes for a minimally invasive cancer-screening technique known ... to be less effective than standard colonoscopy at ... Belgium suggests. , Although able to identify many ...
Cached Medicine News:Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 2Health News:Grubb & Ellis Healthcare REIT Signs Agreement to Purchase 16 Building Medical Office Portfolio 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 2Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 3Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 4Health News:Cornerstone Therapeutics Submits Regulatory Filing for Extended-Release Antitussive Product 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 2Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 3Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 4Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 5Health News:Centocor Ortho Biotech Statement on the FDA ODAC Opinion Regarding DOXIL(R) for Treatment of Advanced Breast Cancer 6Health News:AMN Healthcare Names New Chief Financial Officer 2Health News:AMN Healthcare Names New Chief Financial Officer 3Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 2Health News: Colonoscopy Beats 'Camera Pill' at Catching Colon Cancer 3
... Centuries of German Craftsmanship ... instrumentation in the world. Ocutek ... you! Only holders of the ... and eight-year apprenticeship, are qualified ...
Vertical punch designed to create a 1.5mm clean cylindrical hole. Rotatable for convenient positioning. Flat Handle. Overall length 87mm....
Adjustable piston accommodates 7-9mm trephine blade. Complete punch includes base plate, piston carrier, piston for 7 - 9mm trephine blades and 18mm diameter Teflon block. Designed for accurate donor...
... Centuries of German ... finest surgical instrumentation in ... makes them available to ... the coveted Meisterbrief certificate, ...
Medicine Products: